These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
623 related items for PubMed ID: 29343507
1. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA, ACTIVE investigators. Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507 [Abstract] [Full Text] [Related]
15. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, Li S, Wang Y, Mendelsohn AM, Song M, Zhu Y, Rahman P, McInnes IB, PSUMMIT 1 Study Group. Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1739-49. PubMed ID: 26097039 [Abstract] [Full Text] [Related]
16. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249 [Abstract] [Full Text] [Related]
18. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944 [Abstract] [Full Text] [Related]